LITTLETON, Colo.--(BUSINESS WIRE)--Pico-Tesla, The Magneceutical™ Therapy Company, announced today that it has enrolled the first seven patients for a randomized, double-blind, placebo-controlled Pilot Study of persons who have type 2 diabetes, the most common form of diabetes. The Pilot Study seeks to determine whether the application of magnetic fields generated by the Company’s patented Resonator™ system can be effective as an adjunctive therapy to oral medications in reducing hemoglobin A1c levels. For more information about this Pilot Study, call Pico-Tesla at 303-795-3222.
